Pfizer in talks to merge off-patent drugs business with Mylan in a stock deal; plans to form global generic drug giant: Report

Pfizer Inc plans to combine its off-patent business, which includes Lipitor cholesterol pills and male impotence drug Viagra, with Mylan NV

FP Staff July 29, 2019 09:20:15 IST
Pfizer in talks to merge off-patent drugs business with Mylan in a stock deal; plans to form global generic drug giant: Report
  • Mylan shareholders would receive a little more than 40 percent of the newly formed entity

  • Pfizer Inc plans to combine its off-patent business, which includes Lipitor cholesterol pills and male impotence drug Viagra, with Mylan NV

  • Last year, Pfizer said it was planning to reorganize into three units, separating its consumer healthcare business.

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal.

Pfizer Inc plans to combine its off-patent business, which includes Lipitor cholesterol pills and male impotence drug Viagra, with Mylan NV and form a generic drug giant, according to people familiar with the matter, Bloomberg said.

The deal if completed could be announced as early as Monday, said sources to Bloomberg.

Mylan shareholders would receive a little more than 40 percent of the newly formed entity, with Pfizer shareholders receiving the remainder, according to a source familiar with the matter, reported Reuters adding that Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Pfizer in talks to merge offpatent drugs business with Mylan in a stock deal plans to form global generic drug giant Report

The Pfizer campus in US. Reuters

Separation of Pfizer’s off-patent business would be a tax-free spin-off, the person added.

Last year, Pfizer said it was planning to reorganize into three units, separating its consumer healthcare business.

The restructuring will allow the company to evaluate its businesses better and could result in selling or spinning off its off-patent drugs, Wall Street analysts earlier said.

The Wall Street Journal first reported the talks between the companies on Saturday.

Pfizer and Mylan did not immediately respond to requests for comment.

--With inputs from Reuters

Updated Date:

also read

The interview | Government, vaccine industry nexus compromised health security of US citizens, says Robert F Kennedy, Jr
Opinion

The interview | Government, vaccine industry nexus compromised health security of US citizens, says Robert F Kennedy, Jr

“We believe that at least 650,000 lives were lost because of suppression of effective treatments, such as ivermectin and hydroxychloroquine, among others. By all appearances, the government had a plan and wanted to ram it through at any cost, and it did,” says Kennedy

Pfizer to sell more drugs at cost to poor nations
World

Pfizer to sell more drugs at cost to poor nations

Pfizer, in an announcement at the World Economic Forum meeting in Davos, said it will begin offering at cost to 45 low-income nations the full slate of products for which it has global rights.

WATCH: Pfizer working on new Covid strain to sell vaccines, official tells his date
World

WATCH: Pfizer working on new Covid strain to sell vaccines, official tells his date

During the conversation, a high-level officer made shocking claim that in all probability top employees at Pfizer knew Covid-19 did not originate organically